Trial Profile
A Prospective Randomized Trial to Compare Basal Bolus therapies that use either Insulin Lispro Protamine Suspension or Insulin Glargine together with Lispro Insulin in Patients with Type 2 Diabetes
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary) ; Insulin lispro (Primary) ; Insulin neutral protamine lispro (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms IOPJ
- Sponsors Eli Lilly and Company
- 19 Jan 2022 This trial has been completed in Slovakia (End Date: 25 Feb 2010), according to European Clinical Trials Database record.
- 16 Sep 2011 Primary endpoint 'Proportion-of-glycosylated-haemoglobin' has been met.
- 16 Sep 2011 Results presented at the 47th Annual Meeting of the European Association for the Study of Diabetes.